{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["68(17)"],"submitter":["Ammara A"],"pubmed_abstract":["We report the regioselective chemical derivatization of (<i>R</i>)-2-((4-aminophenethyl)amino)-1-phenylethan-1-ol, the primary metabolite of the β<sub>3</sub>-Adrenergic Receptor (β<sub>3</sub>-AR) agonist mirabegron, with prototypical Carbonic Anhydrase Inhibitors (CAIs) to afford the carbamates <b>10-14</b> and the ureido derivatives <b>15-18</b>. Such compounds were endowed <i>in vitro</i> with distinct inhibition profiles for the human (h) Carbonic Anhydrases (CAs) and showed preferential agonisms for the β<sub>3</sub>-AR subtype. Among them, <b>14</b> induced remarkable intraocular pressure (IOP) lowering in an <i>in vivo</i> transient model of ocular hypertension, with the maximal effect at 120 min post-administration at 1% w/v concentration. Furthermore, the high stability of the co"],"journal":["Journal of medicinal chemistry"],"pagination":["18579-18596"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12434671"],"repository":["biostudies-literature"],"pubmed_title":["Repurposing Drug Metabolites into Dual β-Adrenergic Receptor-Carbonic Anhydrase Modulators as Potential Tools for Ocular Disorders."],"pmcid":["PMC12434671"],"pubmed_authors":["Di Serio C","Carta F","Matucci R","Viita JAO","Marri S","Selleri S","Lucarini L","Villano S","Ammara A","Carone A","Sgambellone S","Eysteinsson T","Kalinin S","Pieraccini G","Luga G","Fittipaldi C","Garcia-Llorca A","Supuran CT","Pecori R","Urtti A"],"additional_accession":[]},"is_claimable":false,"name":"Repurposing Drug Metabolites into Dual β-Adrenergic Receptor-Carbonic Anhydrase Modulators as Potential Tools for Ocular Disorders.","description":"We report the regioselective chemical derivatization of (<i>R</i>)-2-((4-aminophenethyl)amino)-1-phenylethan-1-ol, the primary metabolite of the β<sub>3</sub>-Adrenergic Receptor (β<sub>3</sub>-AR) agonist mirabegron, with prototypical Carbonic Anhydrase Inhibitors (CAIs) to afford the carbamates <b>10-14</b> and the ureido derivatives <b>15-18</b>. Such compounds were endowed <i>in vitro</i> with distinct inhibition profiles for the human (h) Carbonic Anhydrases (CAs) and showed preferential agonisms for the β<sub>3</sub>-AR subtype. Among them, <b>14</b> induced remarkable intraocular pressure (IOP) lowering in an <i>in vivo</i> transient model of ocular hypertension, with the maximal effect at 120 min post-administration at 1% w/v concentration. Furthermore, the high stability of the co","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-01T15:44:54.044Z","creation":"2026-04-08T13:48:52.6Z"},"accession":"S-EPMC12434671","cross_references":{"pubmed":["40857102"],"doi":["10.1021/acs.jmedchem.5c01459"]}}